These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33651454)

  • 21. Safety and tolerability of medications approved for chronic weight management.
    Fujioka K
    Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S7-11. PubMed ID: 25900872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity: Pharmacotherapy.
    Powell A
    FP Essent; 2020 May; 492():25-29. PubMed ID: 32383845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills.
    Gasoyan H; Pfoh ER; Schulte R; Sullivan E; Le P; Rothberg MB
    Diabetes Obes Metab; 2024 May; 26(5):1687-1696. PubMed ID: 38287140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug treatment of obesity in the cardiovascular patient.
    Charakida M; Tousoulis D; Finer N
    Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
    Shyh G; Cheng-Lai A
    Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
    Khalil H; Ellwood L; Lord H; Fernandez R
    Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
    [No Abstract]   [Full Text] [Related]  

  • 27. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S; Dear A; Cowley MA
    Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonincretin drugs in later-stage development.
    Zimmerman MP; Mehr SR
    Am J Manag Care; 2014 Jan; 20(1 Spec No.):E2. PubMed ID: 25618226
    [No Abstract]   [Full Text] [Related]  

  • 29. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
    Krentz AJ; Fujioka K; Hompesch M
    Diabetes Obes Metab; 2016 Jun; 18(6):558-70. PubMed ID: 26936802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE.
    Shibuya K; Ali KF; Ji X; Milinoivh A; Bauman J; Kattan MW; Pantalone KM; Burguera B
    Endocr Pract; 2019 Oct; 25(10):1022-1028. PubMed ID: 31241358
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Obesity: Pharmacotherapy Trends of Office-Based Visits in the United States From 2011 to 2016.
    Claridy MD; Czepiel KS; Bajaj SS; Stanford FC
    Mayo Clin Proc; 2021 Dec; 96(12):2991-3000. PubMed ID: 34728060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    Nuffer W; Trujillo JM; Megyeri J
    Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy for obesity: What you need to know.
    Bersoux S; Byun TH; Chaliki SS; Poole KG
    Cleve Clin J Med; 2017 Dec; 84(12):951-958. PubMed ID: 29244650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
    Chatzis P; Tziomalos K; Pratilas GC; Makris V; Sotiriadis A; Dinas K
    Folia Med (Plovdiv); 2018 Dec; 60(4):512-520. PubMed ID: 31188761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How physician obesity specialists use drugs to treat obesity.
    Hendricks EJ; Rothman RB; Greenway FL
    Obesity (Silver Spring); 2009 Sep; 17(9):1730-5. PubMed ID: 19300434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009-2015.
    Saxon DR; Iwamoto SJ; Mettenbrink CJ; McCormick E; Arterburn D; Daley MF; Oshiro CE; Koebnick C; Horberg M; Young DR; Bessesen DH
    Obesity (Silver Spring); 2019 Dec; 27(12):1975-1981. PubMed ID: 31603630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
    Halpern B; Faria AM; Halpern A
    Expert Rev Clin Pharmacol; 2013 May; 6(3):235-41. PubMed ID: 23656337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort.
    Lewis KH; Fischer H; Ard J; Barton L; Bessesen DH; Daley MF; Desai J; Fitzpatrick SL; Horberg M; Koebnick C; Oshiro C; Yamamoto A; Young DR; Arterburn DE
    Obesity (Silver Spring); 2019 Apr; 27(4):591-602. PubMed ID: 30900410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.
    Sarayani A; Donahoo WT; Hampp C; Brown JD; Winterstein AG
    Ann Intern Med; 2023 Apr; 176(4):443-454. PubMed ID: 36940443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.